Swiss-based Roche has received CE mark approval for its companion diagnostic cobas epidermal growth factor receptor (EGFR) mutation test to treat non-small-cell lung cancer (NSLC).
The cobas EGFR mutation test is a real-time polymerase chain reaction-based diagnostic test that identifies 41 mutations across EGFR gene’s exons 18, 19, 20 and 21.
Go deeper with GlobalData
The EGFR assay that runs on the cobas 4800 system will identify NSLC patients who have mutations in their EGFR gene and who may benefit with the company’s anti-EGFR tyrosine kinase inhibitors – Tarceva (erlotinib).
Tarceva is a once-daily, oral, non-chemotherapy treatment, designed to inhibit EGFR, a protein involved in the growth and development of cancers.
Roche Diagnostics COO Daniel O’Day said the new EGFR test would help health care providers to determine the appropriate course of treatment for individual patients.
"Patients with this genetically distinct form of lung cancer derive great benefit when EGFR inhibitors are used as initial treatment," he added.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
